BOT

0.00%

41.5¢ botanix pharmaceuticals ltd

Objective Views on Lead product: BTX 1503 (Acne), page-7

First 7 Last

Share
Profile

Follow
Woodz13

41 Posts.

1

06/07/20

11:17

Post #: 45664773
Share
Originally posted by T.E.P.: ↑

Botanix is developing BTX 1503 as a novel treatment for moderate to severe acne.

Phase 1:
Botanix successfully completed a Phase 1b study of BTX 1503 during 1Q CY2018
The study achieved all the BTX 1503 program goals, indicating that it has an excellent safety profile, is very effective at reducing the number of inflammatory and non-inflammatory acne lesions, and provided an improvement in patient rated satisfaction
BTX 1503’s (on average) ~47% reduction in inflammatory lesions was greater than any other FDA-approved topical acne product for which data is available after four weeks of treatment

Phase 2:
However, the phase 2 results showed the primary endpoint in reduction in inflammatory lesions did not achieve statistical significance (even when considering AUS v US).
But, the secondary endpoint of reduction in non-inflammatory end points was statistically significant
It is the inflammatory lesions that are important.
Non-inflammatory lesions are simply comedones or pimples that have not yet broken through the skin are are not yet inflamed.

Ultimately, my outsider objective view is that:
The phase 2 trial was not a success
The market evidently agrees with me given the share price collapse
Progression to phase 3 is not guaranteed.

I'm impressed with the caliber of management of this company, but I am not yet convinced by the BTX1503 product.

To the bulls, why are you confident that the trial will continue into phase 3? Why are you confident that the market is wrong and that you are right and that we will return to the highs of old? Has the market overlooked the results of the phase 2 trial?

Willing to be convinced to buy in for a speculative trade -- I can't consider this an "investment" on current data yet.

T.E.P.

Expand

Hmmmmmm, maybe because of this?

'Endpoints in this phase 2 study already mirror those required in phase 3 studies for approval'
Last edited by Woodz13: 06/07/20

BOT Price at posting: 4.2¢ Sentiment: Buy Disclosure: Held
12 Upvote

1 Great analysis

Reply

Top Stories

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

As Nvidia cools, we're looking to Aussie AI

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

CBA breaks trading record on strong day for Aussie financials

There are more pages in this discussion • 41 more messages in this thread...

First 7 Last

Add BOT (ASX) to my watchlist

(20min delay)
Last 41.5¢		Change 0.000(0.00%)		Mkt cap ! $752.8M

Open	High	Low	Value	Volume
41.0¢	43.5¢	41.0¢	$2.989M	7.071M

Buyers (Bids)

No.	Vol.	Price($)
5	408524	41.5¢

Sellers (Offers)

Price($)	Vol.	No.
42.0¢	30000	1

View Market Depth

No.	Vol.	Price($)
3	359035	0.415
6	383895	0.410
8	528535	0.405
12	590183	0.400
7	403387	0.395

Price($)	Vol.	No.
0.420	30000	1
0.425	136193	1
0.430	190093	5
0.435	26426	1
0.440	250447	8

Last trade - 16.10pm 06/09/2024 (20 minute delay)

BOT (ASX) Chart

Objective Views on Lead product: BTX 1503 (Acne), page-7

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Shekel Brainweigh investor presentation webinar – the future of retail automation

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Red Mountain Mining: record gold prices, two projects, two greenstone belts

As Nvidia cools, we're looking to Aussie AI

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

CBA breaks trading record on strong day for Aussie financials

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Objective Views on Lead product: BTX 1503 (Acne), page-7

Top Stories

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Shekel Brainweigh investor presentation webinar – the future of retail automation

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Red Mountain Mining: record gold prices, two projects, two greenstone belts

As Nvidia cools, we're looking to Aussie AI

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

CBA breaks trading record on strong day for Aussie financials

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News